Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 14 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
Follow-Up Questions
¿Cuál es el ratio P/E de Reviva Pharmaceuticals Holdings Inc (RVPH)?
El ratio P/E de Reviva Pharmaceuticals Holdings Inc es N/A
¿Quién es el CEO de Reviva Pharmaceuticals Holdings Inc?
Dr. Laxminarayan Bhat es el President de Reviva Pharmaceuticals Holdings Inc, se unió a la empresa desde 2020.
¿Qué tal es el rendimiento del precio de la acción RVPH?
El precio actual de RVPH es de 0.304, ha decreased un 27.51% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Reviva Pharmaceuticals Holdings Inc?
Reviva Pharmaceuticals Holdings Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Reviva Pharmaceuticals Holdings Inc?
La capitalización bursátil actual de Reviva Pharmaceuticals Holdings Inc es $20.6
¿Es Reviva Pharmaceuticals Holdings Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 8 analistas han realizado calificaciones de análisis para Reviva Pharmaceuticals Holdings Inc, incluyendo 2 fuerte compra, 9 compra, 1 mantener, 0 venta, y 2 fuerte venta
